U.S. Stem Cell, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a USRM research report →
Price Chart
About the company
U. S. Stem Cell, Inc.
- CEO
- Michael Tomas
- IPO
- 2008
- Employees
- 11
- HQ
- Sunrise, FL, US
Get TickerSpark's AI analysis on USRM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $64.15K
- P/E
- -0.02
- PEG
- -0.00
- P/S
- 0.78
- P/B
- -0.00
- EV/EBITDA
- -4.15
- Div Yield
- 0.00%
- Gross Margin
- 71.03%
- Op Margin
- -2096.90%
- Net Margin
- -3483.21%
- ROE
- 20.78%
- ROIC
- 29.95%
Latest fiscal year · YoY change
- Revenue
- $82.05K-59.1%
- Gross Profit
- $58.28K-60.8%
- Op Income
- $-1,720,484
- Net Income
- $-2,857,943+13.1%
- EPS
- $-0.00+32.4%
- OCF Growth
- +71.2%
- FCF Growth
- +71.2%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -48.37
- RSI (14)
- 52
- Avg Volume
- 69.97K
No earnings-call transcripts are available for USRM yet.
- Free Float
- 87.9%
- Shares Outstanding
- 641.51M
- Float Shares
- 563.65M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 25, 22 | Knutson Gregory | other | 2,500,000 |
| Mar 18, 22 | Knutson Gregory | other | 25,000,000 |
| Feb 24, 22 | Knutson Gregory | other | 12,500,000 |
| Feb 24, 22 | Knutson Gregory | other | 12,500,000 |
| Mar 23, 21 | MURPHY WILLIAM P JR | other | 7,518,797 |
| Apr 2, 21 | Knutson Gregory | other | 187,575 |
| Oct 5, 20 | Knutson Gregory | other | 2,035,820 |
| Apr 1, 20 | Knutson Gregory | other | 1,445,647 |
| Feb 17, 21 | Knutson Gregory | other | 3,759,398 |
| Nov 18, 19 | TOMAS MIKE | other | 1,500,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our USRM coverage
Recent articles, reports, and earnings notes.
No research on USRM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate USRM report →